HSP70 Promotes Heat Tolerance Effect of Lung Cancer Cells Through Mediating SUMOylation of HIF-1α

2020 ◽  
Vol 10 (8) ◽  
pp. 1077-1084
Author(s):  
Jun Wan ◽  
Min Zhou ◽  
Xiean Ling ◽  
Guanggui Ding ◽  
Jian Wang

Radiofrequency ablation produces a heat-tolerance effect and increases HIF-1αp, and HSP70 expression is distributed in the lesion, but whether HSP70 mediates HIF-1α SUMOylation in lung cancer cells remains unclear. Mouse lung cancer LLC cells were cultured under hypoxia and randomly assigned into control group, heat tolerance group and HSP70 siRNA group followed by analysis of HSP70 and HIF-1α level by real time PCR and Western blot, association of HIF-1α with SUMO-1 and SUMO-2/3 by immunoprecipitation, SENP-1, Ubc9 and E3 ligase expression. CD4 + T cells were isolated and divided into control group, hyperbaric oxygen group, normal temperature hypoxia group, and high temperature hypoxia group followed by measurement of T17 and Treg cell by flow cytometry, and HIF-1α level. HSP70 and HIF-1α level was increased in heat tolerance group and reduced by HSP70 siRNA. Meanwhile, HSP70 siRNA decreased HSP70 binding to SENP-1, Ubc9, and E3 ligase. Heat tolerance group showed decreased SENP-1 expression, increased Ubc9 and E3 ligase expression. HIF-1 bound to SUMO-1, but not SUMO-2/3. HIF-1α expression was increased in CD4+ T cells in treatment group, with significantly increased CD4+ T cells apoptosis and changes of Treg and Th17 compared to control (P < 0 05). HSP70 can promote the heat tolerance effect of lung cancer cells by promoting SUMO-1 expression of HIF-1α; the heat tolerance effect leads to abnormal cellular immune response, which may affect the therapeutic effect.

2010 ◽  
Vol 127 (11) ◽  
pp. 2612-2621 ◽  
Author(s):  
Minu K. Srivastava ◽  
Jacobus J. Bosch ◽  
Ashley L. Wilson ◽  
Martin J. Edelman ◽  
Suzanne Ostrand-Rosenberg

Lung Cancer ◽  
2012 ◽  
Vol 75 (1) ◽  
pp. 95-101 ◽  
Author(s):  
Hiroyuki Tao ◽  
Yusuke Mimura ◽  
Keisuke Aoe ◽  
Seiki Kobayashi ◽  
Hiromasa Yamamoto ◽  
...  

2018 ◽  
Vol 7 (6) ◽  
pp. e1428156 ◽  
Author(s):  
Éilis Dockry ◽  
Seónadh O'Leary ◽  
Laura E. Gleeson ◽  
Judith Lyons ◽  
Joseph Keane ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Bin Yang ◽  
Yan Wang ◽  
Zhuoying Chen ◽  
Yi-Ming Feng ◽  
Liang-Liang Shi

Objective. To investigate the effects of Apatinib on the “stemness” of lung cancer cells in vivo and to explore its related mechanisms. Methods. A xenograft model of lung cancer cells A549 was established in nude mice and randomized into a control group (n = 4) and an Apatinib group (n = 4). Tumor tissues were harvested after 2 weeks, and mRNA was extracted to detect changes in stemness-related genes (CD133, EPCAM, CD13, CD90, ALDH1, CD44, CD45, SOX2, NANOG, and OCT4) and Wnt/β-catenin, Hedgehog, and Hippo signal pathways. Results. Compared with the control group, the volume and weight of nude mice treated with Apatinib were different and had statistical significance. Apatinib inhibited the expressions of ABCG2, CD24, ICAM-1, OCT4, and SOX2 and upregulated the expressions of CD44, CD13, and FOXD3. Apatinib treatment also inhibited the Wnt/β-catenin, Hedgehog, and Hippo signaling pathways. Conclusion. Apatinib suppressed the growth of non-small-cell lung cancer cells by repressing the stemness of lung cancer through the inhibition of the Hedgehog, Hippo, and Wnt signaling pathways.


2019 ◽  
Vol 18 ◽  
pp. 153473541983076 ◽  
Author(s):  
Hwa Jeong Kang ◽  
Jeehye Kim ◽  
Seong Hyeok Cho ◽  
So-Jung Park ◽  
Hwa-Seung Yoo ◽  
...  

Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells. The combined treatment of HAD-B1 with afatinib inhibited the proliferation of H1975 cells in a dose-dependent manner compared with the treatment of afatinib or HAD-B1 alone. The combined treatment group significantly induced early apoptosis and cell cycle arrest of the cells compared with afatinib- or HAD-B1-treated control group. Profile analysis of cell cycle proteins in H1975 cells treated with the combination of HAD-B1 and afatinib using InnoPharmaScreen antibody microarray showed downregulation of pERK1/2 and upregulation of p16 in the cells. In vivo tumor growth assay in xenograft animal model of human H1975 lung cancer cells revealed that the mean tumor volume in the group treated with the combination of HAD-B1 and afatinib showed a significant reduction compared with the control groups.


2018 ◽  
Vol 49 (1) ◽  
pp. 235-244 ◽  
Author(s):  
Changxuan You ◽  
Yu Yang ◽  
Beili Gao

Background/Aims: CD133+ cancer cells display low sensitivity to anti-cancer treatment; thus, combination treatment with adjuvant drugs is required to improve the efficiency of cancer therapy. The aim of this study was to explore the effect of imperatorin, a linear furanocoumarin compound, on γδ T cell-mediated cytotoxicity against CD133+ lung cancer cells. Methods: CD133+ and CD133- subgroups from A549 and PC9 lung cancer cells were sorted by using flow cytometry. The cytotoxicity of γδ T cells against cancer cells was evaluated by measuring lactate dehydrogenase release. The concentration of tumor necrosis factor-related apoptosis-inducing ligand in the co-culture system was determined by using an enzyme-linked immunosorbent assay. Mitochondrial membrane potential, expression of death receptor 4 (DR4) and DR5 on the cell surface, and rate of apoptosis were measured by flow cytometry. Cytochrome c release and cellular protein expression were detected by western blot analysis. Results: Compared with CD133- cells, CD133+ cells were resistant to γδ T cell-mediated cytotoxicity. However, imperatorin significantly increased the sensitivity of CD133+ lung cancer cells to γδ T cell treatment in vitro and in vivo. Mechanically, we found that myeloid cell leukemia 1 (MCL-1), an important anti-apoptotic protein belonging to the Bcl-2 family, was overexpressed in CD133+ A549 and PC9 cells compared to their corresponding CD133- cells. Co-treatment with imperatorin and γδ T cells suppressed the expression of MCL-1, and thus promoted the mitochondrial apoptosis mediated by γδ T cells in CD133+ A549 and PC9 lung cancer cells. Conclusion: Up-regulated MCL-1 in CD133+ lung cancer cells is responsible for their resistance to γδ T cells. Furthermore, the combination of γδ T cells with imperatorin sensitized CD133+ lung cancer cells to γδ T cell-mediated cytotoxicity by targeting MCL-1.


2017 ◽  
Vol 114 (49) ◽  
pp. 12994-12999 ◽  
Author(s):  
Cornelia Voigt ◽  
Peter May ◽  
Adrian Gottschlich ◽  
Anamarija Markota ◽  
Daniel Wenk ◽  
...  

IL-22 has been identified as a cancer-promoting cytokine that is secreted by infiltrating immune cells in several cancer models. We hypothesized that IL-22 regulation would occur at the interface between cancer cells and immune cells. Breast and lung cancer cells of murine and human origin induced IL-22 production from memory CD4+ T cells. In the present study, we found that IL-22 production in humans is dependent on activation of the NLRP3 inflammasome with the subsequent release of IL-1β from both myeloid and T cells. IL-1 receptor signaling via the transcription factors AhR and RORγt in T cells was necessary and sufficient for IL-22 production. In these settings, IL-1 induced IL-22 production from a mixed T helper cell population comprised of Th1, Th17, and Th22 cells, which was abrogated by the addition of anakinra. We confirmed these findings in vitro and in vivo in two murine tumor models, in primary human breast and lung cancer cells, and in deposited expression data. Relevant to ongoing clinical trials in breast cancer, we demonstrate here that the IL-1 receptor antagonist anakinra abrogates IL-22 production and reduces tumor growth in a murine breast cancer model. Thus, we describe here a previously unrecognized mechanism by which cancer cells induce IL-22 production from memory CD4+ T cells via activation of the NLRP3 inflammasome and the release of IL-1β to promote tumor growth. These findings may provide the basis for therapeutic interventions that affect IL-22 production by targeting IL-1 activity.


2021 ◽  
pp. molcanres.0342.2021
Author(s):  
Haiyun Wang ◽  
Qiuling Huang ◽  
Jianhong Xia ◽  
Shan Cheng ◽  
Duanqing Pei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document